Leucylarginylproline
目录号 : GC32520Leucylarginylproline是血管紧张素转换酶(ACE)抑制剂,IC50值为0.27μM。
Cas No.:133943-59-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment: | Hip-His-Leu (5mM) and an ACE inhibitor (Leucylarginylproline) are dissolved in a 100 mM sodium borate buffer (pH 8.3) containing 300 mM NaCl, and incubated for 30 min with 8 milliunits of ACE at 37°C. The ACE inhibitor concentration required to inhibit 50% of the ACE activity under the above conditions is defined as IC50[1]. |
Animal experiment: | Rats: Leucylarginylproline is dissolved in 1.0 mM normal saline. After being warmed up, rats are orally administered (0.18 mmol/kg bw) with peptides or normal saline (control). Tail systolic blood pressures are measured at 2-h intervals (0, 2, 4, 6, 8, 10, and 12 h) after the administration[2]. |
References: [1]. Miyoshi S, et al. Structures and activity of angiotensin-converting enzyme inhibitors in an alpha-zein hydrolysate. Agric Biol Chem. 1991 May;55(5):1313-8. |
Leucylarginylproline is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 0.27μM.
Intravenous injection of Leucylarginylproline (30mg/kg) causes a decrease in the blood pressure. The maximum mean blood pressure reduction (about 15 mmHg) occurrs about 2 min after the injection[1]. Leucylarginylproline peptide reduces the blood pressure by about 15 mmHg at the fourth hour and shows a maximal reduction effect of about 35 mmHg at the eighth hour after oral administration[2].
[1]. Miyoshi S, et al. Structures and activity of angiotensin-converting enzyme inhibitors in an alpha-zein hydrolysate. Agric Biol Chem. 1991 May;55(5):1313-8. [2]. Chen TL, et al. Microencapsulation and modification of synthetic peptides of food proteins reduces the blood pressure of spontaneously hypertensive rats. J Agric Food Chem. 2003 Mar 12;51(6):1671-5.
Cas No. | 133943-59-6 | SDF | |
Canonical SMILES | Leu-Arg-Pro | ||
分子式 | C17H32N6O4 | 分子量 | 384.47 |
溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.601 mL | 13.0049 mL | 26.0098 mL |
5 mM | 0.5202 mL | 2.601 mL | 5.202 mL |
10 mM | 0.2601 mL | 1.3005 mL | 2.601 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。